Male medication shown to reduce cellulite
Yes, you've read it correctly, it seems that a drug used for male potency, that improves curvature might just be a cure for cellulite. The biopharmaceutical company Auxilium states that the drug for treating penis curvature deformity involving injectable collagenase clostridium histolyticum (CCH) works by targeting and breaking down the collagen tethers found in cellulite regions, which in turn releases the dimpled skin resulting in improved smoothening of the skin’s surface.
What is cellulite and how do male drugs work on removing it?
The report originates from the results of a Phase 2a clinical trial that involved 150 women between the ages of 18 and 45 who each received up to three treatment sessions of drug or placebo. The study consisted of a randomized, double-blind protocol where test subjects were given either high-dose, mid dose, low dose injections of CCH or a placebo injection to their individual cellulite affected regions - chiefly, the thighs and buttocks where significantly dimpling was present.
The report also tells us a little bit about what cellulite is. It states that cellulite is a localized metabolic disorder of tissue under the skin that involves the loss of elasticity or shrinking of collagen cords, called "septae," that attach the skin to the muscle layers below. The result of loss of elasticity and/or shrinking of collagen cords allows accumulated fat to swell and expand around the septae resulting in the characteristic surface dimpling of cellulite.
How does this surprising anti cellulite drug work?
So how well did CCH perform in the study? The latest results demonstrated that of those who received mid to high doses of CCH, 68 percent of patients reported being "Satisfied" or "Very Satisfied" with the results of their treatment, compared to only 34 percent of randomized patients who were given placebo injections. These results concerning the satisfaction related to the anti cellulite treatment were calculated by both the participants, through individual assessment and physicians via a Global Aesthetic Improvement Scale (GAIS).
Using CCH for the treatment of cellulite is reported to be safe and well-tolerated by the majority of test subjects with the most common adverse events being mild to moderate pain and/or discomfort limited to the local injection area. Eighty-six percent of all related adverse events resolved within 21 days, and there was only one serious adverse event in the trial, determined to be unrelated to the treatment drug.
A second clinical trial is planned for early 2015 states the company’s website.